It controls the rate of protein synthesis via the eukaryotic translation initiation factor 4E-binding protein (4E-BP) and ribosomal protein S6 kinase (S6K), and is inhibited by the anti-cancer drug rapamycin [55]. Here, RPS6KB1 is linked to cancer.